aTyr Pharma Announces Fourth Quarter and Full Year 2024 Results and Provides Corporate Update
Topline data from Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis expected in the third quarter of 2025.Fourth positive DSMB ...